#VisualAbstract: Combined anti-PD-1 and anti-CTLA-4 blockade improves survival among patients with BRAF-mutated melanoma and elevated LDH
Click to read the study in the European Journal of Cancer.
Tag: ipilimumab
#VisualAbstract: Nivolumab plus ipilimumab is safe and effective for the treatment of advanced melanoma (CheckMate 218)
Click to read the study in Melanoma Research.
#VisualAbstract: Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group (14.1 ...
Nivolumab plus ipilimumab increases overall survival in patients with malignant pleural mesothelioma
1. Median overall survival in the nivolumab plus ipilimumab group (18.1 months) was substantially greater than in the chemotherapy group ...
#VisualAbstract: Prognosis for advanced melanoma has improved between 2013 to 2017 for patients in the Netherlands
Click to read the study in the European Journal of Cancer.
Adding sargramostim to ipilimumab may improve survival in advanced melanoma
1. Adding sargramostim to ipilimumab for advanced melanoma resulted in improvement in overall survival and fewer adverse events when compared ...
2 Minute Medicine Rewind July 8 – July 14, 2013
Image: PD In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the ...